Gold for adults, silver for infants: Pfizer's Prevnar 2.0 headed to FDA months after Merck's green light
Pfizer was first to the finish line for the next-gen pneumococcal vaccine in adults, but Merck beat its rival with a jab for children …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
